A new class of small molecule drugs, now in phase I clinical trials, is the first to target circadian clock proteins, which play a key role in the recurrence and spread of glioblastoma.
In an innovative new study of glioblastoma, scientists used artificial intelligence to reprogram cancer cells, converting them into dendritic cells, which can identify cancer cells and direct other immune cells to kill them.
